If you feel ill with fever, flu-like symptoms or respiratory illness, please call us to reschedule your appointment. Please Do Not Bring Children Under age 16 to Appointments.

March is Colorectal Cancer Awareness Month!

Originally posted on 3/5/2019
Updated on 3/10/2022

 

By R. Kyle Barnett, MD

Colon cancer is the second leading cause of cancer deaths among men and women combined in the United States, but most cases are preventable with appropriate screening. Efforts to increase colorectal cancer screening are urgently needed.

Who should be screened for colorectal cancer?

The American Cancer Society recommends screening for people at average risk of colorectal cancer at age 45, although some insurance companies have not adapted this recommendation as of yet. Higher risk individuals (for example, those with a family history of colorectal cancer or colorectal polyps, those with a prior history of polyps or those with inflammatory bowel disease) may need to start screening at an earlier age.

How should I be screened?

Various test options are available for colorectal cancer screening.

1. Stool-based tests check the stool for signs of cancer and include fecal immunochemical test (FIT) every year, guaiac-based fecal occult blood test (FOBT) every year or stool DNA test (Cologuard) every 3 years.

2. Visual exams of the colon and rectum look at the structure of the colon and rectum for any abnormal areas and include colonoscopy every 10 years or less, depending on the outcome, CT colonography (virtual colonoscopy) every 5 years or flexible sigmoidoscopy every 5 years.

Note: If a person chooses to be screened with a test other than colonoscopy, any abnormal test result should be followed up with a colonoscopy.

Each test has pros and cons, and one might be a better option for you than another. The most important thing is to GET SCREENED!

My doctor recently recommended a stool DNA test for screening. Is that test as effective as a colonoscopy?

The simple answer is No.

-Cologuard detects the presence of precancerous or cancerous cells by testing DNA from stool samples. It requires no bowel prep, no pre-test diet or medication changes, is done at home and is fairly inexpensive, often covered by insurance.

-However, studies indicate Cologuard detects only 92% of cancers and detects only 42% of precancerous polyps, making it far less effective as a preventative tool.

-It has a 13% false positive rate (meaning the test reads positive in the absence of disease), requiring further testing or confirmation with colonoscopy. This colonoscopy would not be covered by most insurance companies as a screening test; it would be considered a diagnostic test.

-Cologuard must be used for screening every 3 years, as compared to colonoscopy every 10 years – if no polyps were found.

-Colonoscopy detects more than 95% of cancers and more than 80% of all polyps, some of which could be precancerous. In addition, colonoscopy can detect other diseases and allows for the immediate removal of polyps (some of which are precancerous growths).

Does insurance cover my colorectal screening test?

The Affordable Care Act (ACA) requires both private insurers and Medicare to cover the costs of colorectal cancer screening tests. At this time, many, but not all insurers cover the cost of colorectal cancer screening before the age of 50. However, the ACA doesn’t apply to health plans that were in effect before the law was passed in 2010. Check with your insurance provider to be sure.

Make a difference in your life or the life of a loved one. Get screened! Contact Granite Peaks Gastroenterology to schedule your colon cancer screening today.

What is Lynch Syndrome?

By J. David Schmidt, MD

 

Lynch Syndrome is also known as hereditary non-polyposis colorectal cancer. It is the most common cause of inherited colorectal cancer accounting for 3% of all newly diagnosed cases of colorectal cancer and 3% of endometrial cancer. Colorectal cancer is the 2nd leading cause of cancer-related death in the United States.

Lynch Syndrome refers to patients and families with a genetic mutation in one of the DNA mismatch repair (MMR) genes. It is seen in approximately 1 in 279 people in the population. As we age, errors in DNA replication tend to occur more frequently resulting in abnormal genes being produced which produce abnormal function in the body. The role of the DNA mismatch repair system is to maintain correct DNA base pairs and prevent abnormal gene expression that leads to conditions such as cancer. Microsatellite Instability (MSI) is when regions of repetitive DNA sequences fail to be repaired correctly. This is a characteristic of tumors in Lynch Syndrome. However, 15% of sporadic (non-inherited) colorectal cancers demonstrate MSI.

The major clinical manifestation of Lynch Syndrome is colorectal cancer (CRC).  Patients with this condition may be asymptomatic or may have worrisome symptoms such as abdominal pain, blood in their stool, or a change in the pattern of their bowel habits. The lifetime risk of colorectal cancer for Lynch Syndrome varies but can be as high as 47%. Colorectal cancer in Lynch syndrome tends to occur at a younger age (45-60 years) compared to sporadic colon cancer (69 years). Patients with Lynch Syndrome are at risk for more than one location of colon cancer developing at the same time (synchronous) and developing colon cancer again after the initial cancer is found and treated (metachronous).  Seven percent of patients have more than one cancer at the time of diagnosis. The cancers that develop in Lynch Syndrome tend to occur in a different location in the colon compared to sporadic CRC, the right side of the colon also known as the proximal colon. These polyps tend to be large, flat and more aggressive. In Lynch Syndrome, the time it takes a polyp to develop into cancer is relatively short (35 months) compared to sporadic CRC (10-15 years).

Other Cancer Types Associated with Lynch Syndrome

Lynch Syndrome is also associated with diseases outside of the colon; the most common is endometrial (uterine) cancer. Other cancers that are associated with Lynch Syndrome include ovarian, stomach, small bowel, bile duct, ureter, brain (gliomas) and sweat gland tumors (sebaceous neoplasms). A rare condition called Muir-Torre syndrome is a variant of Lynch Syndrome and is characterized by sebaceous tumors.

Lynch Syndrome Diagnosis

The diagnosis of Lynch Syndrome can be challenging and is therefore often overlooked. Different strategies for identifying individuals at risk for the condition consider family history, prediction models, tumor-based testing (which includes MSI testing), and genetic analysis. The Amsterdam I criteria are frequently used and can be simplified by using the “3-2-1 rule.” Patients at risk for Lynch Syndrome will have 3 or more relatives with Lynch Syndrome-related cancers including a first degree relative, 2 generations are affected by Lynch Syndrome related cancers, and 1 or more cancers were diagnosed before age 50 years. Other systems have been proposed for identifying patients at risk; one is known as the Bethesda guidelines.

Lynch Syndrome should be suspected when a patient meets certain criteria. Those criteria include identifying more than one CRC at the time of diagnosis, identifying a second CRC in the same individual over time, diagnosing CRC at an age less than 50 years, or identifying multiple Lynch Syndrome-related cancers (see above).  In order to reach a definitive diagnosis of Lynch Syndrome, an abnormal genetic mutation in the mismatch repair gene (MMR) must be identified.

 

Individuals who may be candidates for genetic testing include the following:

– All newly diagnosed CRC

– Endometrial (uterine) cancer diagnosed before age 60 years

– First degree relative with known MMR/EPCAM genetic mutation

– Newly diagnosed CRC and an elevated risk based on prediction models

– Family history meeting above Amsterdam-type criteria

 

This overview of the Lynch Syndrome focuses on what defines the syndrome and who should be considered for additional testing.

If you have questions about your GI health or how hereditary gastrointestinal conditions may play a part in your overall health picture, contact the gastroenterologists at Granite Peaks Gastroenterology in Sandy or Lehi for answers.

Granite Peaks Welcomes James M. Stewart, MD

James M. Stewart, MD:  “As a gastroenterologist, I believe that gastrointestinal health and well-being are critical to enjoying a healthy lifestyle, and all that Utah has to offer. After completing my gastroenterology training at Banner Good Samaritan/ VA program in Phoenix, Arizona, I am pleased to start practicing at Granite Peaks Gastroenterology in Sandy, Utah and will be serving patients from across the Wasatch Front. My special interests include colorectal cancer prevention, GERD, Inflammatory Bowel Disease, and I’ve done research in obesity-related liver disease and other gastrointestinal cancers. After losing family to gastrointestinal cancers, I am dedicated to promoting screenings for early detection of colorectal and esophageal cancer.”

James M. Stewart, MD will be accepting new patients and provides same and next day availability. Stewart sees patients in our Sandy office, and has procedure time every week. Visit Dr. Stewart’s bio on our Meet the Team page by clicking here.

Fellowship: Gastroenterology, Banner Good Samaritan/ VA Hospital-Phoenix, AZ
Residency: Internal Medicine, University of California, San Diego, CA
Internship: Internal Medicine, Residency Program, University of California, San Diego, CA
Doctor of Medicine: University of Utah, Salt Lake City, UT

 

March 8th: National Colon Cancer Screening Day

March 8th is National Colon Cancer Screening Day!

Colorectal cancer is most common in people 50 and older and those with a family history of the disease or a personal history of colorectal cancer, polyps or inflammatory bowel disease (IBD). Unfortunately, by the time symptoms are present, colorectal cancer can be in an advanced sage. The good news, however, is that colorectal cancer is highly survivable… if it is diagnosed and treated early.

Protect your health with regular screenings…
It can save your life!

Colorectal cancer generally begins as small noncancerous growths called polyps. But with regular screenings, our board-certified gastroenterologists can find and remove these polyps before they become cancerous.

The best defense against colorectal cancer is regular screenings. The American Cancer Society recommends routine colorectal screenings beginning at age 50, earlier for people with higher risks (such as family history). Because it allows direct visual examination of the inside of the entire colon, colonoscopy is considered the “gold standard” screening method.  Also, any precancerous polyps found during the screening can be removed during the procedure, preventing their progression to colorectal cancer.

Granite Peaks Gastroenterology accepts all insurance plans and can see patients in about one week for a colonoscopy screening.

Call (801) 619-9000 or schedule an appointment today!

Close Menu